Literature DB >> 12047769

p53 expression related to the aggressive infiltrative histopathological feature of basal cell carcinoma.

Sauvarat Auepemkiate1, P Boonyaphiphat, P Thongsuksai.   

Abstract

AIMS: To determine whether the p53 protein expression which is involved in the genesis and progression of various malignant tumours may relate to age, sites or the aggressive histopathological feature of the basal cell carcinoma. METHODS ADN
RESULTS: One hundred and fifty-eight basal cell carcinoma specimens from Songklanakarind Hospital, southern Thailand, collected from January 1992 to December 2000, were examined by immunohistochemistry using polyclonal anti-p53-CM1 (Novocastra Laboratories, Newcastle, UK; dilution 1:700). p53 protein expression was demonstrated in 48.7% of cases. The multivariate analysis showed that the aggressive infiltrative histopathological type was significantly associated with p53 expression (odds ratio 2.95, 95% confidence interval 1.10-7.90), whereas age, sun-exposure site, cellular response and fibrosis were not.
CONCLUSIONS: The p53 expression is found to be related to the aggressive histopathological feature, which may be of predictive value for the behaviour of basal cell carcinoma. However, this result does not support the relation between sun exposure inducing basal cell carcinoma and p53 protein expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047769     DOI: 10.1046/j.1365-2559.2002.01393.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  B-Raf mutations, microsatellite instability and p53 protein expression in sporadic basal cell carcinomas.

Authors:  Angeliki Stamatelli; Angelica A Saetta; Thaleia Bei; Nicolaos Kavantzas; Nicolaos V Michalopoulos; Efstratios Patsouris; Kiriaki Aroni
Journal:  Pathol Oncol Res       Date:  2011-01-28       Impact factor: 3.201

2.  Caspase-3, p53 and Bcl-2 expression in basal cell carcinoma of the eyelid.

Authors:  Efe Koyun; Remzi Karadag; Seyma Ozkanli; Serpil Oguztuzun; Arzu Kaya Kocdogan; Isilay Ozsoy
Journal:  Postepy Dermatol Alergol       Date:  2020-09-02       Impact factor: 1.837

3.  TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features.

Authors:  António Castanheira; Maria João Vieira; Mafalda Pinto; Carolina Dias; Luísa Prada; Sofia Macedo; Margarida Sá Fernandes; Fortunato Vieira; Paula Soares; Alberto Mota; José Manuel Lopes; Paula Boaventura
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

4.  Patched knockout mouse models of Basal cell carcinoma.

Authors:  Frauke Nitzki; Marco Becker; Anke Frommhold; Walter Schulz-Schaeffer; Heidi Hahn
Journal:  J Skin Cancer       Date:  2012-09-13

Review 5.  Human Organ-Specific 3D Cancer Models Produced by the Stromal Self-Assembly Method of Tissue Engineering for the Study of Solid Tumors.

Authors:  Vincent Roy; Brice Magne; Maude Vaillancourt-Audet; Mathieu Blais; Stéphane Chabaud; Emil Grammond; Léo Piquet; Julie Fradette; Isabelle Laverdière; Véronique J Moulin; Solange Landreville; Lucie Germain; François A Auger; François Gros-Louis; Stéphane Bolduc
Journal:  Biomed Res Int       Date:  2020-04-13       Impact factor: 3.411

Review 6.  Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.

Authors:  Toshihiko Hoashi; Naoko Kanda; Hidehisa Saeki
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

7.  Immunohistochemical evaluation of p53 and Ki67 expression in skin epithelial tumors.

Authors:  Effat Khodaeiani; Ashraf Fakhrjou; Mehdi Amirnia; Shahla Babaei-Nezhad; Farshid Taghvamanesh; Elham Razzagh-Karimi; Hossein Alikhah
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

8.  Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.

Authors:  L Pilloni; P Bianco; C Manieli; G Senes; P Coni; L Atzori; N Aste; G Faa
Journal:  Eur J Histochem       Date:  2009-06-29       Impact factor: 3.188

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.